Studying Stored Samples From Patients With Localized Prostate Cancer Treated on Clinical Trial NCI-00-C-0154

National Institutes of Health Clinical Center (CC)

Status: Completed

Conditions: Prostate Cancer

Treatments: Procedure: molecular diagnostic method; Procedure: protein expression analysis; Procedure: diagnostic procedure

Study type: Observational

Funder types: NIH

Identifiers

NCT00535834

CDR0000565972

07-C-N214

999907214

Details and patient eligibility

About

RATIONALE: Studying samples of blood in the laboratory from patients before and after treatment may help doctors learn more about the effects of the treatment on cells.

PURPOSE: This clinical trial is studying samples collected from patients with localized prostate cancer who received treatment on clinical trial NCI-00-C-0154.

Full description

OBJECTIVES:

Primary

• Evaluate the formation of antibody complexes in serum samples taken before initiation of treatment and after completion of therapy in prostate cancer patients previously enrolled on clinical trial NCI-00-C-0154.
• Evaluate immunologic response.

Secondary

• Clone the underlying tumor antigens discovered through SEREX.

OUTLINE: Samples previously collected on clinical trial NCI-00-C-0154 (whole blood, serum, and peripheral mononuclear blood cells) are analyzed for immunologic responses and evidence of formation of anti-tumor antibodies. Western blot is used to detect any evidence of vaccine-induced autoantibody responses. If there is an indication of response, SEREX is used to clone the underlying antigens.

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Diagnosis of localized adenocarcinoma of the prostate
• Received treatment on clinical trial NCI-00-C-0154

PATIENT CHARACTERISTICS:

• Consented the use of their collected blood cells for future research while enrolled on NCI-00-C-0154

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics